暨赛国际再生医学集团，是一家同时拥有基因工程技术，干细胞技术、免疫细胞技术、细胞储存、端粒检测等生物技术,集研发，转化和应用为一体的精准医疗高科技企业。集团总部基地设立在国家医疗中心城市广州。基地总占地面积20,000平米，全球总占地面积超100,000平米。遍布北京、广州、香港、海南、广西、东盟、澳大利亚和美国等地区。
暨赛国际再生医学以科研为企业立命之本。公司科研团队由全球最顶尖的再生医学领域专家组成，以2005年诺贝尔生理学或医学奖获得者巴里马歇尔教授，为核心的科学顾问团队。目前公司已建有整体万级，局部百级的cGMP无菌细胞实验室与基因组学实验室。通过共同研发，委托研究，技术收购等方式，已经与全球顶级的生物研究中心及机构建立了科研合作，为大众提供精准的健康管理服务。
在全球范围内不遗余力地推进产学研医共同发展，为人类生命的健康与延续不懈努力，更为人类延缓衰老与疾病预防治疗提供了无限可能。经过十余年的创新发展，暨赛国际已然成为粤港澳大湾区生物技术创新企业50强，广东省生物技术百强企业，国家高新技术企业并入库国家科技部。在全球范围内取得授权资质及核心技术发明专利63项，外观专利13项。获得第六届中国创新创业大赛生物医药组全国总决赛第五名；第二届天青杯暨天英会青年科技创新创业大赛冠军；受邀参加世界顶级科技盛会《财富论坛》科技头脑风暴大会；并列入《广州市生物医药产业发展五年行动计划》重点企业。特别是在诺贝尔生理或医学奖得主，拉尔夫斯坦曼教授的技术成果上研发的，GCTL靶向性细胞治疗技术，更是暨赛国际独有的专利技术，在全球范围的靶向性细胞治疗技术上具有领先地位。为病毒感染患者肿瘤预防,肿瘤患者提供有效的综合防治方案。同时提供干细胞,免疫细胞研发技术，以及为细胞储存的未来提供技术保障和解决方案。
作为再生医学领域的践行者，和精准健康管理的引领者，我们将继续承担关注人类健康的时代使命，紧跟国家战略发展的步伐，致力于成为全球最专业的细胞管家。以造福社会责任担当的情怀，不断地推进人类生命健康事业的发展，带领中国人远离癌症与疾病，让更多家庭拥有健康幸福的生活！
GCH Regenerative Medicine Group, possesses genetic engineering technologies, including stem cell technology, immune cell technology, cell storage, telomere detection, and other biotechnologies.
It is a high-tech precision medicine enterprise that integrates transformation and applications.
Headquartered in Guangzhou, the national center for medical science. GCH Regenerative Medicine Guangzhou office covers an area of 20,000 square meters. The enterprise branch offices combined cover over 100,000 square meters in the world with branches in Beijing, Guangzhou, Hainan, Guangxi, ASEAN countries, Australia, the United States, and other countries and regions.
Scientific research is the foundation of GCH Regenerative Medicine. The company's research team consists of the world's top experts in regenerative medicine, such as Nobel Prize laureate Professor Barry Marshall, winner of the 2005 Nobel Prize for Physiology or Medicine.
Presently, the company has built in total 10,000 grade and locally 100 grade cGMP Aseptic Cell Laboratory and Genomics Laboratory. Through joint research and development, commissioned research and technology acquisitions, GCH Regenerative Medicine has established close scientific research cooperation with the world's top biological research centers, to provide precision health management services to the public.
It has been dedicated to promoting common developments in the industry, education, and global medical research. These are all part of the company’sunremitting efforts in human health and continuation of life. These research provide infinite treatment possibilities in delaying human senility, prevention, and treatment of diseases.
After more than ten years of innovation and developments, GCH Regenerative Medicine has become one of the Greater Bay Area’s Top 50 biotechnology innovation enterprises, the Guangdong's Top 100 biotechnology enterprises. The company has been recognized as a high-tech Chinese enterprise and achieved into China’s Ministry of Science and Technology database. GCH Regenerative Medicine has obtained validated international qualifications, including 63 patents for core technological inventions and 13 product design patents. The company’s long list of acclamations include winning fifth place in the biomedical group of at the 6th Chinese Innovation and Entrepreneurship Competition. GCH Regenerative Medicine was the champion at the 2nd Guangzhou Thero International Innovation and Entrepreneurship Competition. It was also invited to attend the Science and Technology Brainstorming Conference at theFortune Global Forum, the world-leading science and technology forum. GCH Regenerative Medicine has been designated as a key enterprise in the Five-Year Action Plan for Guangzhou Bio-Pharmaceutical Industry Development.
Based on the technological achievements of Nobel laureate in physiology or medicine professor Ralph Steinman, the company researched and developed GCTL targeted therapy technology, which is a unique global leading targeted cell therapy patented technology of GCH Regenerative Medicine. This therapy provides virus-infected patients, and cancer patients with effective and comprehensive prevention therapy. In the meantime, it provides stem cells and immune cell R&D technology, and technical support and solutions for future cell storage.
As a practitioner in the field of regenerative medicine, and a leader in precision health management, GCH Regenerative Medicine will continue to undertake the mission focusing on human health, and commit ourselves to become the world's most professional cell keeper. Our mission is to shoulder our social responsibilities to benefit society, by continuously promotingour health business and development, to help more people stay free from cancer and other diseases, and enable more families to enjoy healthy and happy lives!
